WuXi Biologics to Manufacture VISEN’s Lonapegsomatropin in Chengdu

• WuXi Biologics and VISEN Pharmaceuticals will begin technology transfer for the commercial production of lonapegsomatropin in China.

• The project includes establishing China’s first dual-chamber lyophilised production line and aims to start local production in 2028.

WuXi Biologics, a global CRDMO, has announced the launch of commercial technology transfer for lonapegsomatropin, the core therapeutic asset of VISEN Pharmaceuticals, at its newly established microbial manufacturing site in Chengdu. The project is part of an expanding collaboration between the two companies, which first signed a strategic agreement in December 2023.

The long-acting growth hormone, already approved in the US and Europe, is used for treating paediatric growth hormone deficiency (PGHD). Regulatory approval in China is expected in 2025, with local commercial production targeted for 2028. The therapy, administered weekly, is noted for its improved dosing convenience and clinical profile.

As part of the partnership, WuXi Biologics and VISEN will also co-develop China’s first dual-chamber lyophilised production line. This formulation technology is designed to improve product stability and ease of administration, marking a notable development in contract manufacturing innovation.

Dr. Chris Chen, CEO of WuXi Biologics, commented: “The inaugural commercial project of lonapegsomatropin at our Chengdu microbial manufacturing site underscores clients’ trust in our microbial technology platform and commercial manufacturing capabilities.”

Pony Lu, CEO of VISEN Pharmaceuticals, emphasised the importance of domestic manufacturing as a core strategic priority and described the collaboration as key to translating innovation into patient impact.